Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
601 questions in 75 reviews · Schizophrenia
current versionsNo studies 601 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Contingency management vs standard care Global state · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Contingency management vs standard care Quality of life/life satisfaction · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Motivational interviewing vs standard care Quality of life/life satisfaction ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Skills training vs standard care Substance use: Alcohol (C‐DIS‐R average score) · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Skills training vs standard care Substance use: Drug (non‐alcohol) (C‐DIS‐R average score) · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Skills training vs standard care Mental state · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Skills training vs standard care Quality of life/life satisfaction ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + psychosocial rehabilitation vs standard care Adverse event: Death ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + psychosocial rehabilitation vs standard care Substance use: Alcohol ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + psychosocial rehabilitation vs standard care Substance use: Drug (non‐alcohol) ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + psychosocial rehabilitation vs standard care Mental state ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + psychosocial rehabilitation vs standard care Global State‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + psychosocial rehabilitation vs standard care Quality of life/life satisfaction ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + intensive case management vs standard care Adverse event: Death · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + intensive case management vs standard care Substance use: alcohol ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + intensive case management vs standard care Substance use: Drug (non‐alcohol) ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + intensive case management vs standard care Mental state ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + intensive case management vs standard care Global State ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy + intensive case management vs standard care Quality of life/life satisfaction ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Non‐integrated models of care ‐ Assertive community treatment only/Intensive case management/Specialised case management services vs standard care Adverse event: Death ‐ not measured · people with both severe mental illness and substance misuse Psychosocial interventions for people with both severe mental illness and substance misuse (2019) · Cochrane | no estimate extracted | NR | No studies |
Lorazepam vs Oxazepam Service use: duration of stay in hospital · catatonia in people with schizophrenia or SMI Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses (2019) · Cochrane | no estimate extracted | NR | No studies |
Lorazepam vs Oxazepam Satisfaction with care: clinically important change in satisfaction by informal care‐givers · catatonia in people with schizophrenia or SMI Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses (2019) · Cochrane | no estimate extracted | NR | No studies |
Lorazepam vs Oxazepam Satisfaction with care: clinically important change in satisfaction by recipients of care · catatonia in people with schizophrenia or SMI Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses (2019) · Cochrane | no estimate extracted | NR | No studies |
Lorazepam vs Oxazepam Global state: clinically important change in global state (as defined by individual studies) · catatonia in people with schizophrenia or SMI Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses (2019) · Cochrane | no estimate extracted | NR | No studies |
Lorazepam vs Oxazepam Adverse effects: incidence of clinically important adverse effect · catatonia in people with schizophrenia or SMI Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses (2019) · Cochrane | no estimate extracted | NR | No studies |
Lorazepam vs Oxazepam General functioning: clinically important change in specific aspects of functioning, such as life skills ‒ as defined by each of the studies · catatonia in people with schizophrenia or SMI Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Global state: relapse · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Global state: clinically important change in global state · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Peer outcomes: clinically important change in quality of life for service user and peer supporter · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Adverse events: all cause · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Economic: indirect costs (cost to society) · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs standard care Service use: days in hospital – medium term · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs standard care Global state: relapse · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs standard care Global state: clinically important change in global state · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs standard care Peer outcomes: clinically important change in quality of life for service user and peer supporter · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs standard care Economic: indirect costs (cost to society) · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Service use: hospital admission · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Peer support plus standard care vs clinician‐led support plus standard care Service use: days in hospital · people with schizophrenia or other serious mental illness Peer support for people with schizophrenia or other serious mental illness (2019) · Cochrane | no estimate extracted | NR | No studies |
Haloperidol discontinuation vs haloperidol continuation Mental state: clinically important change in general mental state · schizophrenia Haloperidol discontinuation for people with schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
Haloperidol discontinuation vs haloperidol continuation General functioning: clinically important change in general functioning including working ability · schizophrenia Haloperidol discontinuation for people with schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
Haloperidol discontinuation vs haloperidol continuation General behaviour: clinically important change in general behaviour · schizophrenia Haloperidol discontinuation for people with schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
Haloperidol discontinuation vs haloperidol continuation Quality of life: clinically important change in quality of life · schizophrenia Haloperidol discontinuation for people with schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs sham‐ECT plus standard care Response to treatment Clinically important response to treatment as defined by each study · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs antipsychotics plus standard care Satisfaction and acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs antipsychotics plus standard care General functioning Clinically important change in general functioning as defined by each study · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs antipsychotics plus standard care Service use ‐ hospitalisation · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs antipsychotics plus standard care Adverse event/effect(s) ‐ death · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs sham‐ECT plus standard care Cognitive functioning Clinically important change in cognitive functioning as defined by each study · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs standard care Service use ‐ hospitalisation · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |
ECT plus standard care vs standard care Adverse event/effect(s) ‐ death · people with treatment‐resistant schizophrenia Electroconvulsive therapy for treatment‐resistant schizophrenia (2019) · Cochrane | no estimate extracted | NR | No studies |